Building upon this discovery, we evaluated the IGG-Clin risk-score, based on the HER2DX genomic assay for HER2+ breast cancer, which comprehensively assesses both the expression of the IGG signature and tumor stage. Here, ERBB2 is linked to breast carcinoma.